Venmax Drugs & Pharmaceuticals Complete Financial Statements
In FY2026, Venmax Drugs & Pharmaceuticals (VENMAX) reported revenue ₹8 Cr, net profit ₹0 Cr and EPS ₹0.21. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see Venmax Drugs & Pharmaceuticals share price today.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
VENMAX Revenue, Net Profit & EBITDA — Year-on-Year Growth
VENMAX YoY (March 2025 vs March 2026) — revenue +300.0%, expenses +300.0%. Also explore VENMAX share price charts to track price trends across different timeframes.
VENMAX Income Statement — Revenue, EBITDA & Net Profit
Venmax Drugs & Pharmaceuticals revenue ₹8 Cr, EBITDA ₹0 Cr, net profit ₹0 Cr, EPS ₹0.21 (2026). Analyse VENMAX FII DII holdings to track promoter, FII and institutional holdings.
| Particulars | March 2026 | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8 | 2 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 2 | 2 |
| Expenses | 8 | 2 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 2 | 3 |
| EBITDA | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | -1 | 0 | 0 |
| Operating Profit Margin % | 2.00% | -131.00% | 0.00% | 0.00% | 0.00% | -198.00% | -54.00% | -158.00% | 0.00% | -238.00% | -7.00% | -5.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | -1 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | -1 | 0 | 0 |
| Earnings Per Share (₹) | 0.21 | -0.02 | 0.12 | 0.43 | 3.52 | -0.31 | -0.52 | -0.45 | -0.46 | -2.55 | -0.26 | -0.15 |
VENMAX Balance Sheet — Assets, Liabilities & Shareholders' Equity
VENMAX total assets ₹16 Cr, total equity ₹14 Cr, total liabilities ₹ Cr (2026).
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| Total Assets | 16 | 5 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 4 |
| Current Assets | 16 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 4 |
| LIABILITIES | ||||||||||||
| Total Liabilities | ||||||||||||
| Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Non-Current Liabilities | ||||||||||||
| SHAREHOLDERS' EQUITY | ||||||||||||
| Total Equity | 14 | 4 | -1 | -1 | -1 | -3 | -3 | -2 | -2 | -2 | 0 | 0 |
| Share Capital | 12 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves & Surplus | 3 | -6 | -6 | -6 | -6 | -8 | -8 | -8 | -7 | -7 | -5 | -5 |
VENMAX Cash Flow Statement — Operating, Investing & Financing
Venmax Drugs & Pharmaceuticals operating cash flow ₹-2 Cr, investing ₹0 Cr, financing ₹5 Cr, net cash flow ₹3 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -2 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | -1 | 0 | 0 |
| Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Financing Activities | 5 | 0 | 0 | -2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Net Cash Flow | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |